B

Biogen

D
BIIB
USD
-0.92
(-0.555%)
Market Closed
163,069.00
حجم التداول
14.33
الربح لكل سهم
-
العائد الربحي
20.787
P/E
24,010,865,067.28
حجم السوق
اليوم
-0.5550%
1 اسبوع
-5.215%
1 شهر
-13.931%
6 اشهر
-27.329%
12 اشهر
-26.842%
بداية السنة
-36.336%
كل الوقت
-42.857%
avatar
sara abdelazim
عدد النقاط
112
عدد التوصيات
2

Title:
Biogen

Sector:
Healthcare
Industry:
Drug Manufacturers - General
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
هل تحتاج مساعدة او لديك استفسار؟